HighVista Strategies’s United Therapeutics UTHR Stock Holding History

HighVista Strategies’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Buy	2,095 +581	+38%	+$327K	0.26%	108
2026 Q1	$898K	Sell	1,514 -816	-35%	-$406K	0.25%	120
2025 Q4	$1.14M	Buy	+2,330	New	+$1.09M	0.29%	99
2024 Q3	–	Sell	-1,409	Closed	-$449K	–	170
2024 Q2	$449K	Buy	+1,409	New	+$373K	0.16%	118
2024 Q1	–	Sell	-2,299	Closed	-$506K	–	156
2023 Q4	$506K	Hold	2,299	–	–	0.18%	118
2023 Q3	$519K	Buy	2,299 +557	+32%	+$128K	0.24%	105
2023 Q2	$385K	Sell	1,742 -1,462	-46%	-$324K	0.18%	128
2023 Q1	$718K	Hold	3,204	–	–	0.58%	58
2022 Q4	$891K	Sell	3,204 -662	-17%	-$167K	0.53%	54
2022 Q3	$809K	Buy	3,866 +414	+12%	+$92.6K	0.46%	57
2022 Q2	$813K	Buy	3,452 +795	+30%	+$162K	0.49%	45
2022 Q1	$477K	Sell	2,657 -3,609	-58%	-$688K	0.3%	73
2021 Q4	$1.35M	Buy	6,266 +362	+6%	+$71.1K	1.08%	28
2021 Q3	$1.09M	Buy	+5,904	New	+$1.16M	0.72%	47

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

HighVista Strategies's UTHR Position: Q2 2026 in Review

HighVista Strategies increased its United Therapeutics (UTHR) stake by 38% in Q2 2026, buying an estimated $327K and bringing the position to 2,095 shares worth $1.14M. The position accounts for 0.26% of the portfolio, ranked #108.

HighVista Strategies first reported a position in UTHR in Q3 2021 and has held it in 14 quarters since. The position peaked at $1.35M in Q4 2021. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

HighVista Strategies held 2,095 shares of United Therapeutics worth $1.14M as of Q2 2026.
HighVista Strategies bought 581 United Therapeutics shares in Q2 2026, an estimated $327K.
United Therapeutics made up 0.26% of HighVista Strategies's portfolio in Q2 2026, its #108 holding.
HighVista Strategies first reported a position in United Therapeutics in Q3 2021 and has held it in 14 quarters since.
HighVista Strategies's United Therapeutics position peaked at $1.35M in Q4 2021.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.